- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.
Merck KGaA shares tested one-year highs Friday after the Food & Drug Administration approved rare form of skin cancer treatment that could cost patients as much as $13,000 per month.
European markets are mixed amid a pause in the global equity market rally after a slumping dollar helped Asia shares to their best weekly gain in more than six months.
AstraZeneca said Friday that it had received a second "complete response letter" from the U.S. FDA regarding its Hyperkalaemia treatment, putting the drug's approval process in the United States doubt.